FONDAZIONE EBRIS

Their core work

FONDAZIONE EBRIS (European Biomedical Research Institute of Salerno) is a biomedical research foundation specializing in microbiome science, multi-omics analysis, and the gut-brain axis. Their flagship work investigates how gut microbiome alterations — including dysbiosis and increased intestinal permeability — drive neuro-inflammation and contribute to neurodevelopmental conditions such as autism spectrum disorder. They integrate genomic, metabolomic, and environmental data through systems biology approaches to find mechanistic links between microbiome composition and human health outcomes. Beyond disease-focused research, they engage in international coordination to build shared standards and data infrastructures for human microbiome research globally.

What they specialise in

How they've shifted over time

EBRIS entered H2020 with a tightly scoped disease focus: autism spectrum disorder, examined through the lens of gut microbiome disruption, intestinal permeability, and neuro-inflammation using multi-omics tools. Their more recent participation shifted toward the broader landscape of human microbiome science — international coordination, data standards, health data science, and personalized medicine — suggesting a deliberate move from niche disease research toward infrastructure-building and translational application. The trajectory points to an institute that started as a specialist in a single condition and is repositioning itself as a credible player in the wider microbiome field.

EBRIS is moving from disease-specific multi-omics research toward international microbiome coordination and data standardization, making them an increasingly relevant partner for clinical trial networks and cross-national microbiome initiatives.

How they like to work

EBRIS has demonstrated the capacity to lead complex international research as coordinator of GEMMA, a multi-partner RIA project. Their 30 unique partners across 12 countries from just two projects indicates they operate within large, diverse consortia rather than small bilateral arrangements. The combination of a coordination role in a research action and a participation role in a support action suggests they are comfortable both driving scientific agendas and contributing as a specialist within coordination networks.

EBRIS has built a network of 30 unique consortium partners spanning 12 countries through only two projects, reflecting the international scope of both their autism research consortium and the global human microbiome coordination action. Their network is predominantly European but extends to international partners given IHMCSA's explicit international cooperation mandate.

What sets them apart

EBRIS is one of very few Italian biomedical research institutes positioned at the intersection of autism research and microbiome science, with hands-on experience coordinating a large-scale multi-omic clinical study. Their dual footprint — as both a disease-focused research coordinator and a participant in international microbiome standard-setting — gives them credibility across the full pipeline from basic science to translational coordination. For a consortium needing Italian expertise in gut-brain axis research or microbiome clinical protocols, EBRIS offers both the scientific depth and the project management track record.

Highlights from their portfolio

• GEMMA
  Largest project by budget (EUR 2.3M), with EBRIS as coordinator of an ambitious multi-omic RIA integrating genome, microbiome, metabolome, and environment data to investigate autism — a rare combination of neurodevelopmental and microbiome science at scale.
• IHMCSA
  Participation in the International Human Microbiome Coordination and Support Action positions EBRIS within the global effort to standardize microbiome research methods and data, extending their reach well beyond Italian or European boundaries.